Recent performance snapshot and what it might signal

With no single headline event driving attention, Cooper Companies (COO) is drawing interest after a period of weaker share performance, including a return of about a 23% decline over the past year and a 35% decline over the past 3 years.

The recent pattern of share price returns, with a 1 month decline of 11.13% and a 1 year total shareholder return of 24.23% in the red, indicates weakening momentum as investors reassess growth prospects and risk.

If you are comparing Cooper Companies with other healthcare names using AI, now could be a good time to scan the market using our screener for 33 healthcare AI stocks

With Cooper Companies trading at a discount to some intrinsic estimates and below certain analyst price targets, the key question is whether recent weakness leaves mispriced value on the table or the market already sees slower growth ahead.

Most Popular Narrative: 31.5% Undervalued

Cooper Companies last closed at $62.36, while the most followed narrative pegs fair value at about $91, which points to a sizeable valuation gap built on specific growth and margin expectations.

The company recently resolved its manufacturing constraints for MyDAY, its premium daily silicone hydrogel contact lens, and is now accelerating global rollout with expanded fitting sets, trial lenses, and over 30 new private label contracts. This is expected to drive substantial revenue growth and market share gains as pent up demand is fulfilled and the premium offering captures higher margins over time.

To see what kind of revenue trajectory and margin lift would need to materialize to support a fair value in the high $80s to low $90s range, and what earnings multiple analysts think that implies over the next few years, the full narrative lays out the exact assumptions behind that target in clear detail.

Result: Fair Value of $91.07 (UNDERVALUED)

However, you also need to weigh softer contact lens demand and ongoing pressure in fertility and IUD products, which could keep revenue growth and margins under strain.

Another angle on valuation

The narrative model points to fair value of about $91 per share and labels Cooper Companies as 31.5% undervalued, but the current P/E of 30.3x is higher than both its 27.1x fair ratio and the US Medical Equipment average of 23.6x, which suggests a richer pricing. Is the gap a margin of safety or a valuation trap?

To see what the numbers say about this price, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The combination of weaker recent returns and an undervaluation narrative has investors divided, so it makes sense to review the facts yourself and act promptly. To see what others are optimistic about and to pressure test your own view, check the 3 key rewards.

Looking for more investment ideas?

Do not stop with a single stock. Broaden your watchlist now so you are ready when the next opportunity lines up with your goals.

• Target higher quality potential by scanning companies that look cheap on fundamentals using our screener for 50 high quality undervalued stocks.
• Prioritize resilience and sleep better at night by focusing on businesses in the 70 resilient stocks with low risk scores.
• Spot future market leaders early by checking the screener containing 25 high quality undiscovered gems before attention and valuations catch up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.